‼️ Hey #ESMO26 family!
Great discussion by Funda Meric-Bernstam on the rationale behind ADC + IO combinations!! @UTMDAnderson
▪️ADCs may induce immunogenic cell death, release DAMPs and prime the TME
▪️They may also increase PD-L1 expression and help overcome antigen heterogeneity
▪️VEGF–PD-(L)1 bispecifics aim to reverse vascular immunosuppression and improve tumour immune access
@OncoAlert @OncoReporte @myESMO @_SEOM
121 浏览 · 7 赞 · 5 转发 · 0 回复
First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours
https://esmocongress.esmo.orgPhase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.orgLITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI
https://esmocongress.esmo.org来源：Mario Balsa · x.com